# US 2006/0051785 A1 · Secreted and transmembrane polypeptides and nucleic acids encoding the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051785 A1
- Document ID: US20060051785A1
- Status: Published application
- Kind: A1
- Application number: 11/151,868
- Filed: 2005-06-13
- Published: 2006-03-09
- Earliest claimed: 1998-06-18
- Inventors: Audrey Goddard; Austin Gurney; Paul Godowski; Victoria Smith; William Wood
- Web page: https://patentgrep.com/patent/US20060051785A1

## CPC

- C07K 14/47: from mammals
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/82: Translation products from oncogenes
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/575: for cancer
- G01N 33/5752: of the lungs
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57555: of the prostate
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

## Claims

### Claim 1

A diagnostic method, comprising determining, in a test biological sample obtained from a mammalian subject, the level of nucleic acid encoding a PRO1104 polypeptide of SEQ ID NO:2 relative to the level of said nucleic acid in a corresponding normal biological sample wherein increased level of said nucleic acid in the test biological sample is indicative that the test biological sample contains cancerous cells.

### Claim 2 (depends on 1)

The method of claim 1 wherein the test and normal biological samples are tissue samples.

### Claim 3 (depends on 2)

The method of claim 2 wherein the test tissue sample is from colon, lung, or breast tissue.

### Claim 4 (depends on 3)

The method of claim 3 wherein the normal biological sample is from the same type of tissue as the test biological sample.

### Claim 5 (depends on 4)

The method of claim 4 wherein the normal biological sample is an epithelial tissue sample from a combination of tissues.

### Claim 6 (depends on 5)

The method of claim 5 wherein epithelial tissue sample includes epithelial cells from colon, lung, or breast tissue.

### Claim 7 (depends on 1)

The method of claim 1 wherein the nucleic acid levels are determined by hybridization of nucleic acid obtained from the test and normal biological samples to one or more probes specific for the nucleic acid encoding PRO1104.

### Claim 8 (depends on 6)

The method of claim 6 wherein hybridization is performed under stringent conditions.

### Claim 9 (depends on 8)

The method of claim 8 wherein said stringent conditions use 50% formamide, 5×SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC and 50% formamide at 55° C., followed by a wash comprising of 0.1×SSC containing EDTA at 55° C.

### Claim 10 (depends on 7)

The method of claim 7 wherein the nucleic acids obtained from the test and normal biological samples are cDNAs.

### Claim 11 (depends on 10)

The method of claim 10 wherein the nucleic acids obtained from the test and normal biological samples are placed on microarrays.

### Claim 12

A diagnostic method comprising determining the expression level of the PRO1104 polypeptide of SEQ ID NO:2 in test biological sample relative to a normal biological sample, wherein overexpression of said polypeptide in the test biological sample is indicative that the sample contains cancerous cells.

### Claim 13 (depends on 12)

The method of claim 12 wherein the test and normal biological samples are tissue samples.

### Claim 14 (depends on 13)

The method of claim 13 wherein the test tissue sample is from colon, lung, or breast tissue.

### Claim 15 (depends on 14)

The method of claim 14 wherein overexpression is detected with an antibody that specifically binds to the PRO1104 polypeptide.

### Claim 16 (depends on 15)

The method of claim 15 wherein said antibody is a monoclonal antibody.

### Claim 17 (depends on 16)

The method of claim 16 wherein said antibody is a humanized antibody.

### Claim 18 (depends on 17)

The method of claim 17 wherein said antibody is an antibody fragment.

### Claim 19 (depends on 18)

The method of claim 18 wherein said antibody is labeled.
